scholarly journals Trends in strong opioid prescribing in Ireland: a repeated cross‐sectional analysis of a national pharmacy claims database between 2010 and 2019

2021 ◽  
Author(s):  
B. A. Norris ◽  
A. Smith ◽  
S. Doran ◽  
M. Barry
Keyword(s):  
Cross Sectional ◽  
Claims Database ◽  
Opioid Prescribing ◽  
Strong Opioid ◽  
Cross Sectional Analysis ◽  
Pharmacy Claims ◽  
Sectional Analysis

scholarly journals Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database

2015 ◽  
Vol 6 (4) ◽  
pp. 627-634 ◽  
Author(s):  
Kimberly G. Brodovicz ◽  
Yong Chen ◽  
Zhiwen Liu ◽  
Mary E. Ritchey ◽  
Jane Liao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Medical Insurance ◽  
Cross Sectional ◽  
Claims Database ◽  
Cross Sectional Analysis ◽  
Sectional Analysis

scholarly journals Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database

2019 ◽  
Vol 23 (2) ◽  
pp. 166-173 ◽  
Author(s):  
Shuji Uno ◽  
Rei Goto ◽  
Kenshi Suzuki ◽  
Kosuke Iwasaki ◽  
Tomomi Takeshima ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Health Insurance ◽  
Medical Costs ◽  
Current Treatment ◽  
Treatment Patterns ◽  
Cross Sectional ◽  
Claims Database ◽  
Cross Sectional Analysis ◽  
Health Insurance Claims ◽  
Sectional Analysis

Abstract P274: Cross-sectional Analysis of Baseline Characteristics for New Users of Vorapaxar (PAR-1 Antagonist) and P2Y 12 Inhibitors

Circulation ◽  
2018 ◽  
Vol 137 (suppl_1) ◽  
Author(s):  
Cathy Anne Pinto ◽  
Gregory P. Hess ◽  
Eileen Fonseca ◽  
John Acquavella
Keyword(s):  
Arterial Disease ◽  
Baseline Period ◽  
Hospital Data ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Pharmacy Claims ◽  
Baseline Characteristics ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Sectional Analysis

Introduction: Vorapaxar is indicated for the reduction of thrombotic events in patients with a prior myocardial infarction (MI) or peripheral arterial disease (PAD), and contraindicated in patients with a prior stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH). This is the first descriptive study of vorapaxar in US clinical practice. Objectives: Main objective was to describe baseline characteristics of vorapaxar new users. For context, P2Y 12 new users were also examined, with indications summarized in Table 1. Methods: Cross-sectional analysis of vorapaxar new users ≥18 years with ≥1 prescription between June 2014 - June 2016 identified in Symphony Health’s outpatient pharmacy claims database linked to private practitioner claims and hospital data. Concomitant clopidogrel use was defined with overlapping days of supply. Medical history was defined using a 1-year baseline period. Results: The analysis included 1,362 vorapaxar (44% with clopidogrel), 975,023 clopidogrel, 133,724 ticagrelor, and 98,101 prasugrel new users (Table 1). Most ticagrelor (87%) and prasugrel (85%) users had evidence of coronary artery disease (CAD) compared with 52% of clopidogrel and 58% of vorapaxar users. In contrast, <1% of ticagrelor and prasugrel users had PAD but no CAD vs. 6% of clopidogrel and 15% of vorapaxar users. The proportion of vorapaxar users (44%) with PAD, alone or with CAD, was 3-5 times larger than P2Y 12 users. PAD was more prevalent for vorapaxar with (50%) vs. without (39%) clopidogrel. Contraindications were infrequent for vorapaxar users - no ICH, <4% with stroke or TIA. Median time from recent MI to therapy start was 6 months for vorapaxar vs. 3 days for ticagrelor and prasugrel and 7 days for clopidogrel. Vorapaxar users were mostly male and on average ~65 years old. Conclusions: The majority of vorapaxar new users had a history of CAD and/or PAD, with PAD prevalence more than twice that of P2Y 12 new users. Contraindications were infrequent.

Evaluation of the prevalence and nutritional and social determinants of overweight in a population of schoolchildren: a cross-sectional analysis of 5,037 children

2012 ◽  
Vol 58 (4) ◽  
pp. 472-476 ◽  
Author(s):  
Caroline Filla Rosaneli ◽  
Flavia Auler ◽  
Carla Barreto Manfrinato ◽  
Claudine Filla Rosaneli ◽  
Caroline Sganzerla ◽  
...  
Keyword(s):  
Social Determinants ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Sectional Analysis

Quantitative Clinical Characteristics of 53 Patients with MPS VII: A Cross-Sectional Analysis

2017 ◽  
Vol 48 (S 01) ◽  
pp. S1-S45
Author(s):  
M. Zielonka ◽  
S. Garbade ◽  
S. Kölker ◽  
G. Hoffmann ◽  
M. Ries
Keyword(s):  
Clinical Characteristics ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Mps Vii ◽  
Sectional Analysis

Fracture prevalence in children 0-19 years-old in Mexico: A 10-year cross-sectional analysis

2019 ◽  
Author(s):  
Patricia Clark ◽  
Annarella Barbato ◽  
Miguel Angel Guagnelli ◽  
Jose Alberto Rascon ◽  
Edgar Denova ◽  
...  
Keyword(s):  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Fracture Prevalence ◽  
Sectional Analysis

2174-PUB: Profiling of Young Diabetes in India: A Cross-Sectional Analysis Report

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2174-PUB
Author(s):  
NARAYANAN NK ◽  
CS DWARAKANATH ◽  
VENKATARAMAN S ◽  
MANIKANDAN RM ◽  
NARENDRA BS ◽  
...  
Keyword(s):  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Sectional Analysis
Sign in / Sign up

Export Citation Format

Share Document